Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA) (Q24310684)

1

0 references

Christine Luong

2

0 references

Joseph D Ho

3

0 references

John R Somoza

4

0 references

Erik Gjerstad

5

0 references

Jie Tang

6

0 references

Steven R Williams

7

0 references

Erik Verner

8

0 references

Wendy B Young

10

0 references

Paul A Sprengeler

11

0 references

Hedy Chan

12

0 references

Kyle Mortara

13

0 references

James W Janc

14

0 references

Mary E McGrath

Journal of Molecular Biology

15

0 references

language of work or name

English

0 references

publication date

19 November 2004

0 references

published in

0 references

volume

344

0 references

issue

2

0 references

page(s)

527-47

0 references

cites work

Activation of blood coagulation factor VIIa with cleaved tissue factor extracellular domain and crystallization of the active complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

The urokinase-type plasminogen activator system in cancer metastasis: A review

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

High-throughput screening of enzyme inhibitors: automatic determination of tight-binding inhibition constants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

The 2.3 A crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Recruiting Zn2+ to mediate potent, specific inhibition of serine proteases

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Expression and purification of a soluble tissue factor fusion protein with an epitope for an unusual calcium-dependent antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Synthesis and X-ray crystal structures of substituted fluorobenzene and benzoquinone inhibitors of the tissue factor VIIa complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

On the size of the active site in proteases. I. Papain

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

The influence of residue 190 in the S1 site of trypsin-like serine proteases on substrate selectivity is universally conserved

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-directed Serine Protease Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Hydrogen bond stereochemistry in protein structure and function

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Development of potent and selective factor Xa inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Optimization of a screening lead for factor VIIa/TF.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-Pyridinylguanidines

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Design, synthesis, and structure-activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

The structure of the extracellular region of human hepsin reveals a serine protease domain and a novel scavenger receptor cysteine-rich (SRCR) domain

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

An ester bond linking a fragment of a serine proteinase to its serpin inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

A novel approach to serine protease inhibition: kinetic characterization of inhibitors whose potencies and selectivities are dramatically enhanced by Zinc(II).

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Contribution of multicentered short hydrogen bond arrays to potency of active site-directed serine protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Design and synthesis of potent and highly selective thrombin inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Selective inhibition of urokinase by substituted phenylguanidines: quantitative structure-activity relationship analyses

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Aromatic amidines. Comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin, and trypsin

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Polymer-assisted solution-phase library synthesis and crystal structure of alpha-ketothiazoles as tissue factor VIIa inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Design, Synthesis, and Crystal Structure of Selective 2-Pyridone Tissue Factor VIIa Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Synthesis and crystal structures of substituted benzenes and benzoquinones as tissue factor VIIa inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Design of benzamidine-type inhibitors of factor Xa

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase.

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Human beta-tryptase is a ring-like tetramer with active sites facing a central pore

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Design of potent selective zinc-mediated serine protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Free R value: a novel statistical quantity for assessing the accuracy of crystal structures

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Determination of the operational molarity of solutions of bovine α-chymotrypsin, trypsin, thrombin and factor Xa by spectrofluorimetric titration

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Structural basis for chemical inhibition of human blood coagulation factor Xa

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

(4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Polyoma middle T-induced vascular tumor formation: the role of the plasminogen activator/plasmin system

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Crystal structure of the catalytic domain of human plasmin complexed with streptokinase

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021

Inhibitors of the protease domain of urokinase-type plasminogen activator

1 reference

https://api.crossref.org/works/10.1016%2FJ.JMB.2004.09.032

7 January 2021